VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate if VTX958 is safe and effective in adult
participants with active Psoriatic Arthritis. Approximately 195 eligible participants will
take VTX958 Dose A, VTX958 Dose B, or matching placebo (no active drug) for 16 weeks. The
study will include 16 weeks of treatment and a 30-day follow-up period.